Article: Case report: JAK inhibition as promising treatment option of fatal RVCLS due to
2023 Volume 14, Page(s) 1118369
Abstract: Introduction: Autosomal dominant mutations in the C-terminal part of : Methods: We collected clinical data of an extended family with RVCLS (: Results: We report clinical details from 29 family members with 17 of them showing RVCLS symptoms. ... ...
Abstract | Introduction: Autosomal dominant mutations in the C-terminal part of Methods: We collected clinical data of an extended family with RVCLS ( Results: We report clinical details from 29 family members with 17 of them showing RVCLS symptoms. Treatment of the index patient with ruxolitinib for >4 years was well-tolerated and clinically stabilized RVCLS activity. Moreover, we noticed normalization of initially elevated Discussion: We provide evidence that JAK inhibition as RVCLS treatment appears safe and could slow clinical worsening in symptomatic adults. These results encourage further use of JAK inhibitors in affected individuals together with monitoring of |
---|---|
Language | English |
Publishing date | 2023-02-21 |
Publishing country | Switzerland |
Document type | Case Reports |
ZDB-ID | 2564214-5 |
ISSN | 1664-2295 |
ISSN | 1664-2295 |
DOI | 10.3389/fneur.2023.1118369 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.